• Inborn errors of metabolism

Nulibry Generic Name & Formulations

General Description

Fosdenopterin 9.5mg (equivalent to 12.5mg fosdenopterin hydrobromide as a dihydrate); per vial; lyophilized pwd or cake for IV infusion after reconstitution; preservative-free; contains mannitol.

Pharmacological Class

Cyclic pyranopterin monophosphate (cPMP).

How Supplied

Single-dose vial (5mL)—1

Generic Availability


Nulibry Indications


To reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A.

Nulibry Dosage and Administration

Adults and Children

Initiate treatment if patient has a diagnosis or presumptive diagnosis; discontinue if presumptive diagnosis is not confirmed by genetic testing. Administer by IV infusion pump once daily at a rate of 1.5mL/min. <37 weeks (preterm neonates): initially 0.4mg/kg, then 0.7mg/kg at Month 1, and 0.9mg/kg at Month 3. ≥37 weeks (term neonates): initially 0.55mg/kg, then 0.75mg/kg at Month 1, and 0.9mg/kg at Month 3. ≥1yr: 0.9mg/kg.

Nulibry Contraindications

Not Applicable

Nulibry Boxed Warnings

Not Applicable

Nulibry Warnings/Precautions


Avoid or minimize exposure to direct sun or UV light (eg, UVA or UVB phototherapy). Advise use of precautionary measures for photosensitivity (eg, protective clothing, hats, sunscreen). Pregnancy. Nursing mothers.

Nulibry Pharmacokinetics

See Literature

Nulibry Interactions


Do not mix or administer with other drugs.

Nulibry Adverse Reactions

Adverse Reactions

Catheter-related complications, pyrexia, viral infection, pneumonia, otitis media, vomiting, cough/sneezing, viral upper respiratory infection, gastroenteritis, bacteremia, diarrhea; photosensitivity.

Nulibry Clinical Trials

See Literature

Nulibry Note

Not Applicable

Nulibry Patient Counseling

See Literature